المؤلفون: N. N. Koloskova, A. Q. Eyyubova, A. O. Shevchenko, Н. Н. Колоскова, А. Г. Эйюбова, А. О. Шевченко

المصدر: Russian Journal of Transplantology and Artificial Organs; Том 26, № 1 (2024); 88-96 ; Вестник трансплантологии и искусственных органов; Том 26, № 1 (2024); 88-96 ; 2412-6160 ; 1995-1191

مصطلحات موضوعية: лист ожидания, heart transplantation, cardiopulmonary exercise test, 6-minute walk test, atrial natriuretic peptide, asthenia, waiting list, трансплантация сердца, кардиореспираторный нагрузочный тест, тест 6-минутной ходьбы, натрийуретический пептид, синдром общей слабости

وصف الملف: application/pdf

العلاقة: https://journal.transpl.ru/vtio/article/view/1682/1566Test; Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22 (8): 1342–1356. doi:10.1002/ejhf.1858.; Daneshvar DA, Czer LS, Phan A, Trento A, Schwarz ER. Heart transplantation in the elderly: why cardiac transplantation does not need to be limited to younger patients but can be safely performed in patients above 65 years of age. Ann Transplant. 2010; 15 (4): 110–119.; Поляков ДС, Фомин ИВ, Беленков ЮН, Мареев ВЮ, Агеев ФТ, Артемьева ЕГ и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021; 61 (4): 4–14.; Marcondes-Braga FG, Vieira JL, Souza Neto JD, Calado G, Ayub-Ferreira SM, Bacal F, Clausell N. Emerging Topics in Heart Failure: Contemporaneous Management of Advanced Heart Failure. Arq Bras Cardiol. 2020; 115 (6): 1193–1196.; Zhao HL, Cui W. Prognostic risk scores for patients with heart failure. Br J Hosp Med (Lond). 2021; 83 (5): 118–132. https://doi.org/10.12968/hmed.2021.0594Test.; Canepa M, Fonseca C, Chioncel O, Laroche C, CrespoLeiro MG, Coats AJS et al. ESC HF Long Term Registry Investigators. Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail. 2018; 6 (6): 452–462.; Simpson J, Jhund PS, Lund LH, Padmanabhan S, Claggett BL, Shen L et al. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020; 5 (4): 432–441.; Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol. 2003; 92: 1350–1354.; Writing Committee; Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77 (6): 772–810.; Попцов ВН, Золотова ЕН. Трансплантация сердца у реципиентов с сахарным диабетом. Вестник трансплантологии и искусственных органов. 2018; 20 (1): 120–126.; Caraballo C, Desai NR, Mulder H, Alhanti B, Wilson FP, Fiuzat M et al. Clinical implications of the New York Heart Association classification. J Am Heart Assoc. 2019; 8 (23): e014240.; Stout KK, Broberg CS, Book WM, Cecchin F, Chen JM, Dimopoulos K et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016; 133 (8): 770–801.; Ross HJ, Law Y, Book WM, Broberg CS, Burchill L, Cecchin F et al. Transplantation and mechanical circulatory support in congenital heart disease a scientific statement from the American Heart Association. Circulation. 2016; 133 (8): 802–820.; Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016; 4 (10): 816–822.; Wasserman K. Coupling of external to cellular respiration during exercise: the wisdom of the body revisited. Am J Physiol. 1994; 266: 519–539.; Sietsema KE, Sue DY, Stringer WW, Ward SA. Wasserman & Whipp’s principles of exercise testing and interpretation. 6th ed. Philadelphia: Wolters Kluwer; 2021.; Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016; 47 (2): 429–460. doi:10.1183/13993003.00745-2015.; Mezzani A, Corrà U, Bosimini E, Giordano A, Giannuzzi P. Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity. Am Heart J. 2003; 145 (6): 1102–1107.; Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA et al. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20 (1): 3–15.; Agostoni P, Dumitrescu D. How to perform and report a cardiopulmonary exercise test in patients with chronic heart failure. Int J Cardiol. 2019; 288: 107–113.; Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L et al. EACPR/AHA scientific statement: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012; 126 (18): 2261–2274.; Wagner J, Agostoni P, Arena R, Belardinelli R, Dumitrescu D, Hager A et al. The role of gas exchange variables in cardiopulmonary exercise testing for risk stratification and management of heart failure with reduced ejection fraction. Am Heart J. 2018; 202: 116–126.; Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun X-G, Whipp BJ. Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications. 5th Edn. Philadelphia: Lippincott Williams & Wilkins, 2011.; Weisman IM, Marciniuk D, Martinez FJ, Sciurba F, Sue D, Myers J et al. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003; 167: 211–277.; O’Neill JO, Young JB, Pothier CE, Lauer MS. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation. 2005; 111: 2313–2318.; Cattadori G, Agostoni P, Corra U, Di Lenarda A, Sinagra G, Veglia F et al. Severe heart failure prognosis evaluation for transplant selection in the era of beta blockers: role of peak oxygen consumption. Int J Cardiol. 2013; 168: 5078–5081.; Bentley DJ, Newell J, Bishop D. Incremental exercise test design and analysis: implications for performance diagnostics in endurance athletes. Sports Med. 2007; 37 (7): 575–586.; Löllgen H, Leyk D. Exercise testing in sports medicine. Dtsch Arztebl Int. 2018; 115: 409–416.; Guazzi M, Dickstein K, Vicenzi M, Arena R. Sixminute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights. Circ Heart Fail. 2009; 2 (6): 549–555.; Zielińska D, Bellwon J, Rynkiewicz A, Elkady MA. Prognostic Value of the Six-Minute Walk Test in Heart Failure Patients Undergoing Cardiac Surgery: A Literature Review. Rehabil Res Pract. 2013; 2013: 965494.; Maldonado-Martín S, Brubaker PH, Eggebeen J, Stewart KP, Kitzman DW. Association between 6-minute walk test distance and objective variables of functional capacity after exercise training in elderly heart failure patients with preserved ejection fraction: a randomized exercise trial. Arch Phys Med Rehabil. 2017; 98 (3): 600–603.; Будневский АВ, Кравченко АЯ, Токмачев РЕ, Черник ТА, Токмачев ЕВ, Летникова ЮБ. Диагностические, прогностические и терапевтические возможности использования теста 6-минутной ходьбы у пациентов с хронической сердечной недостаточностью. Кардиоваскулярная терапия и профилактика. 2020; 19 (6): 2460. doi:10.15829/1728-8800-2020-2460.; Uszko-Lencer NHMK, Mesquita R, Janssen E, Werter C, Brunner-La Rocca HP, Pitta F et al. Reliability, construct validity and determinants of 6-minute walk test performance in patients with chronic heart failure. Int J Cardiol. 2017; 240: 285–290.; Cheetham C, Taylor R, Burke V, O’Driscoll G, Green DJ. The 6-minute walk test does not reliably detect changes in functional capacity of patients awaiting cardiac transplantation. J Heart Lung Transplant. 2005; 24 (7): 848–853.; Omar HR, Guglin M. The longitudinal relationship between six-minute walk test and cardiopulmonary exercise testing, and association with symptoms in systolic heart failure: analysis from the ESCAPE trial. Eur J Intern Med. 2017; 40: e26–e28.; Farag EM, Al-Daydamony MM, Gad MM. What is the association between left ventricular diastolic dysfunction and 6-minute walk test in hypertensive patients? J Am Soc Hypertens. 2017; 11: 158–164.; Lansa Ch, Ciderc A, Nylanderdand E, Brudin L. The relationship between six-minute walked distance and health-related qualityof life in patients with chronic heart failure. Scand Cardiovasc J. 2022 Dec; 56 (1): 310–315. https://doi.org/10.1080/14017431.2022.2107234Test.; Alahdab MT, Mansour IN, Napan S, Stamos TD. Six minute walk test predicts long-term all-cause mortality and heart failure rehospitalization in African-American patients hospitalized with acute decompensated heart failure. J Card Fail. 2009; 15 (2): 130–135.; McCabe N, Butler J, Dunbar SB, Higgins M, Reilly C. Six-minute walk distance predicts 30-day readmission after acute heart failure hospitalization. Heart Lung. 2017; 46 (4): 287–292.; Yap J, Lim FY, Gao F, Teo LL, Lam CS, Yeo KK. Correlation of the New York heart association classification and the 6-minute walk distance: a systematic review. Clin Cardiol. 2015; 38 (10): 621–628.; Shah MR, Hasselblad V, Gheorghiade M, Adams KF Jr, Swedberg K, Califf RM, O’Connor CM. Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2001; 88 (9): 987–993.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166 (1): 111–117.; Nixon PA, Joswiak ML, Fricker FJ. A sixminute walk test for assessing exercise tolerance in severely ill children. J Pediatr. 1996; 129: 362–366.; Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 158 (4): 1185–1189.; Omar HR, Guglin M. Prognostic value of 6-minute walk test and cardiopulmonary exercise test in acute heart failure (from the ESCAPE trial). American Heart Journal Plus: Cardiology Research and Practice. 2021: 1; 42–51.; Grundtvig M, Eriksen-Volnes T, Ørn S, Slind EK, Gullestad L. 6 min walk test is a strong independent predictor of death in outpatients with heart failure. ESC Heart Fail. 2020 Oct; 7 (5): 2904–2911.; Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019; 21 (6): 715–731.; Brunner-La Rocca HP, Sanders-van Wijk S. Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev. 2019; 5 (1): 44–49.; Алиева АМ, Резник ЕВ, Гасанова ЭТ, Жбанов ИВ, Никитин ИГ. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архив внутренней медицины. 2018; 8 (5): 333–345.; Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016; 18: 891–975.; Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American college of cardiology / American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017; 136: e137–e161.; Hogenhuis J, Jaarsma T, Voors AA, Hillege HL, Lesman I, van Veldhuisen DJ. Correlates of B-type natriuretic peptide and 6-min walk in heart failure patients. Int J Cardiol. 2006; 108 (1): 63–67.; Norman JF, Pozehl BJ, Duncan KA, Hertzog MA, Elokda AS, Krueger SK. Relationship of Resting B-type Natriuretic Peptide Level to Cardiac Work and Total Physical Work Capacity in Heart Failure Patients. J Cardiopulm Rehabil Prev. 2009; 29 (5): 310–313.; Kato TS, Collado E, Khawaja T, Kawano Y, Kim M, Farr M et al. Value of Peak Exercise Oxygen Consumption Combined With B-type Natriuretic Peptide Levels for Optimal Timing of Cardiac Transplantation. Circ Heart Fail. 2013; 6 (1): 6–14.; Chen SM, Wu PJ, Wang LY, Wei CL, Cheng CI, Fang HY et al. Optimizing exercise testing-based risk stratification to predict poor prognosis after acute heart failure. ESC Heart Failure. 2023 Apr. 10 (2): 895–906. https://doi.org/10.1002/ehf2.14240Test.; Mancini DM, Eisen H, Kussmaul W, MullR, Edmunds LH Jr, Wilson JR. Value ofpeak exercise oxygen consumption foroptimal timing of cardiac transplantation in ambulatory patients with heartfailure. Circulation. 1991; 83: 778–786.; Peterson LR, Schechtman KB, Ewald GA, Geltman EM, de las Fuentes L, Meyer T et al. Timing of cardiac transplantation in patients with heart failure receiving β-adrenergic blockers. J Heart LungTransplant. 2003; 22 (10): 1141–1148.; Goda A, Lund LH, Mancini D. The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. J Heart Lung Transplant. 2011; 30 (3): 315–325.; Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016; 35 (1): 1–23.; Dunlay SM, Park SJ, Joyce LD, Daly RC, Stulak JM, McNallan SM et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant. 2014; 33 (4): 359–365.; Moayedi Y, Duero Posada JG, Foroutan F, Goldraich LA, Alba AC, MacIver J, Ross HJ. The prognostic significance of frailty compared to peak oxygen consumption and B-type natriuretic peptide in patients with advanced heart failure. Clin Transplant. 2018; 32 (1): e13158.; https://journal.transpl.ru/vtio/article/view/1682Test

الإتاحة: https://doi.org/10.15825/1995-1191-2024-1-88-96Test
https://doi.org/10.1002/ejhf.1858Test
https://doi.org/10.12968/hmed.2021.0594Test
https://doi.org/10.1183/13993003.00745-2015Test
https://doi.org/10.15829/1728-8800-2020-2460Test
https://doi.org/10.1080/14017431.2022.2107234Test
https://doi.org/10.1002/ehf2.14240Test
https://journal.transpl.ru/vtio/article/view/1682Test

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, V. L. Ostanko, N. N. Terentyeva, I. K. Livshits, A. A. Shalovay, O. F. Sibireva, M. A. Solovtsov

المصدر: Бюллетень сибирской медицины, Vol 19, Iss 3, Pp 128-136 (2020)

مصطلحات موضوعية: хроническая сердечная недостаточность, классификация, стадия, функциональный класс, левый желудочек, фракция выброса, диастолическая функция, хроническое легочное сердце, тест 6-минутной ходьбы, диагностическое заключение, Medicine

وصف الملف: electronic resource

العلاقة: https://bulletin.ssmu.ru/jour/article/view/2997Test; https://doaj.org/toc/1682-0363Test; https://doaj.org/toc/1819-3684Test

الوصول الحر: https://doaj.org/article/2ab39b9064bb4a1d8b25f1c3e59e7a57Test

المؤلفون: A. A. Shmalts, А. А. Шмальц

المساهمون: This article was prepared with the support of Bayer, Статья подготовлена при поддержке АО «Байер»

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 3 (2022); 342-349 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 3 (2022); 342-349 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: тест 6-минутной ходьбы, легочная артериальная гипертензия, хроническая тромбоэмболическая легочная гипертензия, специфические легочные вазодилататоры, ЛАГ-специфическая терапия

وصف الملف: application/pdf

العلاقة: https://www.rpcardio.com/jour/article/view/2757/2323Test; Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Российские клинические рекомендации, 2020 [цитировано 10.03.2022. Доступно из: https://cr.minzdrav.gov.ru/recomend/159_1Test].; Чазова И.Е., Мартынюк Т.В., Валиева З.С., и др. Евразийские клинические рекомендации по диагностике и лечению легочной гипертензии (2019). Евразийский Кардиологический Журнал. 2020;(1):78-124. DOI:10.24411/2076-4766-2020-10002.; Чазова И.Е., Мартынюк Т.В., Валиева З.С., и др. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский Кардиологический Журнал. 2021;(1):6-43. DOI:10.38109/2225-1685-2021-16-43.; Galié N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119. DOI:10.1093/eurheartj/ehv317.; Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119-23. DOI:10.1016/S0140-6736(01)06250-X.; Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. DOI:10.1056/NEJMoa012212.; Galiè N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-100. DOI:10.1016/S0140-6736(08)60919-8.; Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol. 2004;43(7):1149-53. DOI:10.1016/j.jacc.2003.10.056.; Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-57. DOI:10.1056/NEJMoa050010.; Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151(4):851.e1-5. DOI:10.1016/j.ahj.2005.09.006.; Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010-9. DOI:10.1161/CIRCULATIONAHA.107.742510.; Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-18. DOI:10.1056/NEJMoa1213917.; Sitbon O, Channick R, Chin KM, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015;373(26):2522-33. DOI:10.1056/NEJMoa1503184.; Ghofrani HA, Galiè N, Grimminger F, et al. PATENT-1 Study Group. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330-40. DOI:10.1056/NEJMoa1209655.; Ghofrani HA, D'Armini AM, Grimminger F, et al. CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319-29. DOI:10.1056/NEJMoa1209657.; Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(6):573-84. DOI:10.1016/S2213-2600(20)30532-4.; Olschewski H, Simonneau G, Galiè N, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-9. DOI:10.1056/NEJMoa020204.; Liu HL, Chen XY, Li JR, et al. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. Chest. 2016;150(2):353-66. DOI:10.1016/j.chest.2016.03.031.; Lajoie AC, Lauzière G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291-305. DOI:10.1016/S22132600(16)00027-8.; Boucly A, Savale L, Jaïs X, et al. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2021;204(7):842-54. DOI:10.1164/rccm.202009-3698OC.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. DOI:10.1164/ajrccm.166.1.at1102.; Глушко Л.А., Шмальц А.А. Оценка состояния кардиореспираторной системы при легочной гипертензии, ассоциированной с врожденными пороками сердца. Креативная Кардиология. 2021;15(2):167-79. DOI:10.24022/19973187-2021-15-2-167-179.; Demir R, Küçükoğlu MS. Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol. 2015;15(3):249-54. DOI:10.5152/akd.2015.5834.; Deboeck G. The 6-min walk test in pulmonary arterial hypertension: only for bad news? Respiration. 2015;89(5):363-4. DOI:10.1159/000377708.; Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8. DOI:10.1016/s0735-1097(02)02012-0.; Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012;126(3):349-56. DOI:10.1161/CIRCULATIONAHA.112.105890.; Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013;143(2):315-323. DOI:10.1378/chest.12-0270.; Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. DOI:10.1183/09031936.00092311.; Souza R, Channick RN, Delcroix M, et al. Association between six-minute walk distance and longterm outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS One. 2018;13(3):e0193226. DOI:10.1371/journal.pone.0193226.; Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153(6):1037-47. DOI:10.1016/j.ahj.2007.02.037.; Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192-201. DOI:10.1016/j.jacc.2012.01.083.; Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 Pt 1):487-92. DOI:10.1164/ajrccm.161.2.9906015.; Costa GOS, Ramos RP, Oliveira RKF, et al. Prognostic value of six-minute walk distance at a South American pulmonary hypertension referral center. Pulm Circ. 2020;10(2):2045894019888422. DOI:10.1177/2045894019888422.; Groepenhoff H, Vonk-Noordegraaf A, van de Veerdonk MC, et al. Prognostic relevance of changes in exercise test variables in pulmonary arterial hypertension. PLoS One. 2013;8(9):e72013. DOI:10.1371/journal.pone.0072013.; Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant. 2011;30(9):982-9. DOI:10.1016/j.healun.2011.03.011.; Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015;34(3):362-8. DOI:10.1016/j.healun.2014.08.020; Zelniker TA, Huscher D, Vonk-Noordegraaf A, et al. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. Clin Res Cardiol. 2018;107(6):460-70. DOI:10.1007/s00392-018-1207-5.; Heresi GA, Rao Y. Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension. Lung. 2020;198(6):933-8. DOI:10.1007/s00408-02000402-w.; Gaine S, Simonneau G. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev. 2013;22(130):487-94. DOI:10.1183/09059180.00006213.; Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med. 2010;16 Suppl 1:S1-9. DOI:10.1097/01.mcp.0000370205.22885.98.; Chakinala MM, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulm Circ. 2013;3(3):507-22. DOI:10.1086/674456.; Frost AE, Badesch DB, Miller DP, et al. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest. 2013;144(5):1521-9. DOI:10.1378/chest.12-3023.; McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S97-S107. DOI:10.1016/j.jacc.2009.04.007.; Gomberg-Maitland M, Bull TM, Saggar R, et al. New trial designs and potential therapies for pulmonary artery hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D82-91. DOI:10.1016/j.jacc.2013.10.026.; Sitbon O, Gomberg-Maitland M, Granton J, et al. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801908. DOI:10.1183/13993003.019082018.; Мартынюк Т.В., Шмальц А.А., Горбачевский С.В., Чазова И.Е. Оптимизация специфической терапии легочной гипертензии: возможности риоцигуата. Терапевтический Архив. 2021;93(9):1117-24. DOI:10.26442/00403660.2021.09.201014.; Huang J, Mehta S, Mura M. Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension. Respiration. 2015;89(5):365-73. DOI:10.1159/000370124.; Naeije R. The 6-min walk distance in pulmonary arterial hypertension: "Je t'aime, moi non plus". Chest. 2010;137(6):1258-60. DOI:10.1378/chest.10-0351.; Jaïs X, D'Armini AM, Jansa P, et al. Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52(25): 2127-34. DOI:10.1016/j.jacc.2008.08.059.; Zeren M, Demir R, Sinan UY, et al. Prevalence of musculoskeletal pain and its impact on quality of life and functional exercise capacity in patients with pulmonary arterial hypertension. Respir Med. 2022;193:106759. DOI:10.1016/j.rmed.2022.106759.; Ozcan Kahraman B, Ozsoy I, Akdeniz B, et al. Test-retest reliability and validity of the timed up and go test and 30-second sit to stand test in patients with pulmonary hypertension. Int J Cardiol. 2020;304:159-163. DOI:10.1016/j.ijcard.2020.01.028.; Degano B, Sitbon O, Savale L, et al. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. Chest. 2010;137(6):1297-303. DOI:10.1378/chest.09-2060.; Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest. 2019;155(3):565-86. DOI:10.1016/j.chest.2018.11.030; Шмальц А.А., Горбачевский С.В. Систематический обзор как основа клинических рекомендаций: рекомендации CHEST-2019 по терапии легочной артериальной гипертензии у взрослых. Терапевтический Архив. 2019;91(12):105-14. DOI:10.26442/00403660.2019.12.000468.; Kim NH, D'Armini AM, Grimminger F, et al. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart. 2017;103(8):599-606. DOI:10.1136/heartjnl-2016-309621.; Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest. 2008;134(2):229-36. DOI:10.1378/chest.072681.; Gilbert C, Brown MCJ, Cappelleri JC, et al. Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest. 2009;135(1):137-42. DOI:10.1378/chest.07-0275.; Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(5):42833. DOI:10.1164/rccm.201203-0480OC.; Lee WT, Peacock AJ, Johnson MK. The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. Eur Respir J. 2010;36(6):1294-301. DOI:10.1183/09031936.00155009.; La Patra T, Baird GL, Goodman R, et al. Remote Six-Minute Walk Testing in Patients with Pulmonary Hypertension: A Pilot Study. Am J Respir Crit Care Med. 2022;205(7):851-4. DOI:10.1164/rccm.202110-2421LE.; https://www.rpcardio.com/jour/article/view/2757Test

الإتاحة: https://doi.org/10.20996/1819-6446-2022-06-09Test
https://doi.org/10.24411/2076-4766-2020-10002Test
https://doi.org/10.38109/2225-1685-2021-16-43Test
https://doi.org/10.1093/eurheartj/ehv317Test
https://doi.org/10.1016/S0140-6736Test(01)06250-X
https://doi.org/10.1056/NEJMoa012212Test
https://doi.org/10.1016/S0140-6736Test(08)60919-8
https://doi.org/10.1016/j.jacc.2003.10.056Test
https://doi.org/10.1056/NEJMoa050010Test
https://doi.org/10.1016/j.ahj.2005.09.006Test

المؤلفون: T. A. Atabekov, R. E. Batalov, S. I. Sazonova, A. M. Gusakova, S. N. Krivolapov, M. S. Khlynin, S. V. Popov

المصدر: Кардиоваскулярная терапия и профилактика, Vol 20, Iss 3 (2021)

مصطلحات موضوعية: внезапная сердечная смерть, желудочковая тахиаритмия, кардиовертер-дефибриллятор, тест 6-минутной ходьбы, st-2, галектин-3, фракция выброса левого желудочка, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://cardiovascular.elpub.ru/jour/article/view/2676Test; https://doaj.org/toc/1728-8800Test; https://doaj.org/toc/2619-0125Test

الوصول الحر: https://doaj.org/article/5e88d2ed8c084553923236a17cdc4c57Test

المؤلفون: Novoselova, E. V., Egorova, E. A., Vishneva, E. M., Новосёлова, Э. В., Егорова, Е. А., Вишнева, Е. М.

المصدر: Сборник статей

مصطلحات موضوعية: 6–MINUTE WALK TEST (6MTH), KCCQ QUESTIONNAIRE, CHRONIC HEART FAILURE (CHF), ТЕСТ 6–МИНУТНОЙ ХОДЬБЫ (6МТХ), ОПРОСНИК KCCQ, ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ (ХСН)

وصف الملف: application/pdf

العلاقة: Сборник статей "V Международная (75 Всероссийская) научно-практическая конференция "Актуальные вопросы современной медицинской науки и здравоохранения". 2020. №1; Новосёлова, Э. В. Тест 6-минутной ходьбы и опросник KCCQ в диагностике у пациентов со сниженной толерантностью к физической нагрузке / Э. В. Новосёлова, Е. А. Егоров, Е. М. Вишнева // Актуальные вопросы современной медицинской науки и здравоохранения : сборник статей V Международной (75 Всероссийской) научно-практической конференции. – 2020. – №1. – С. 335-338.; http://elib.usma.ru/handle/usma/2223Test

الإتاحة: http://elib.usma.ru/handle/usma/2223Test

المؤلفون: Sychov, O. S., Romaniuk, P. B., Sribna, O. V., Hurianov, V. H.

المصدر: Achievements of Clinical and Experimental Medicine; No. 3 (2017) ; Достижения клинической и экспериментальной медицины; № 3 (2017) ; Здобутки клінічної і експериментальної медицини; № 3 (2017) ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2017.v1.i3

مصطلحات موضوعية: permanent atrial fibrillation, heart rate control, exercise capacity, treadmill test, 6-minute walk test, постоянная форма фибрилляции предсердий, контроль частоты сердечных сокращений, толерантность к физическим нагрузкам, тредмил-тест, тест 6-минутной ходьбы, постійна форма фібриляції передсердь, контроль частоти серцевих скорочень, толерантність до фізичних навантажень, тредміл-тест, тест 6-хвилинної ходьби

وصف الملف: application/pdf

العلاقة: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175/7659Test; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175Test; https://repository.tdmu.edu.ua//handle/123456789/13766Test

الإتاحة: https://doi.org/10.11603/1811-2471.2017.v1.i3.8175Test
https://doi.org/10.11603/1811-2471.2017.v1.i3Test
https://repository.tdmu.edu.ua//handle/123456789/13766Test
https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175Test

المؤلفون: Sychov, O. S., Romaniuk, P. B., Sribna, O. V., Hurianov, V. H.

المصدر: Achievements of Clinical and Experimental Medicine; No. 3 (2017) ; Достижения клинической и экспериментальной медицины; № 3 (2017) ; Здобутки клінічної і експериментальної медицини; № 3 (2017) ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2017.v1.i3

مصطلحات موضوعية: permanent atrial fibrillation, heart rate control, exercise capacity, treadmill test, 6-minute walk test, постоянная форма фибрилляции предсердий, контроль частоты сердечных сокращений, толерантность к физическим нагрузкам, тредмил-тест, тест 6-минутной ходьбы, постійна форма фібриляції передсердь, контроль частоти серцевих скорочень, толерантність до фізичних навантажень, тредміл-тест, тест 6-хвилинної ходьби

وصف الملف: application/pdf

العلاقة: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175/7659Test; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175Test

الإتاحة: https://doi.org/10.11603/1811-2471.2017.v1.i3.8175Test
https://doi.org/10.11603/1811-2471.2017.v1.i3Test
https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/8175Test

المؤلفون: Sirenko, Yu. M., Zhyvylo, I. О., Sirenko, O. Yu.

المصدر: Bukovinian Medical Herald; Vol. 21 No. 4 (84) (2017); 114-119 ; Буковинский медицинский вестник; Том 21 № 4 (84) (2017); 114-119 ; Буковинський медичний вісник; Том 21 № 4 (84) (2017); 114-119 ; 2413-0737 ; 1684-7903

مصطلحات موضوعية: pulmonary hypertension, right heart catheterization, 6-minute walk test, легочная гипертензия, катетеризация правых отделов сердца, тест 6-минутной ходьбы, легенева гіпертензія, катетеризація правих відділів серця, тест 6-хвилинної ходьби

وصف الملف: application/pdf

العلاقة: http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XXI.4.84.2017.131/123955Test; http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XXI.4.84.2017.131Test

الإتاحة: https://doi.org/10.24061/2413-0737.XXI.4.84.2017.131Test
http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XXI.4.84.2017.131Test

المؤلفون: A. M. Chernyavsky, A. G. Edemsky, Alexander M. Chernyavsky, A. R. Tarkova, V. G. Efimenko, S. N. Ivanov, Александр Михайлович Чернявский, Александр Геннадьевич Едемский, Михаил Александрович Чернявский, Александра Романовна Таркова, Валентина Геннадьевна Ефименко, Сергей Николаевич Иванов

المصدر: Translational Medicine; № 2 (2014); 72-77 ; Трансляционная медицина; № 2 (2014); 72-77 ; 2410-5155 ; 2311-4495 ; 10.18705/2311-4495-2014-0-2

مصطلحات موضوعية: MSCT-angiography of the pulmonary artery, хроническая постэмболическая легочная гипертензия, тест 6-минутной ходьбы, катетеризация правых отделов сердца, МСКТ-ангиография легочных артерий, pulmonary thromboendarterectomy, chronic postembolic pulmonary hypertension, test with 6-minute walk, right heart catheterization

وصف الملف: application/pdf

العلاقة: https://transmed.almazovcentre.ru/jour/article/view/27/28Test; Narayana Iyengar R.M., Hegde D., Chattuparambil B., Gupta R. et al. Postoperative management of pulmonary endarterectomy and outcome // Ann. Card. Anaesth. - 2012. - № 13. - P. 22-27.; Reesink H.J., van der Plas M.N., Verhey N.E., van Steenwijk R.P. et al. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension // Thorac. Cardiovasc. Surg. - 2011. - № 133. - P. 510-516.; Bando K., Armitage J.M., Paradis I.L., Keenan R.J. et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension // J. Thorac. Cardiovasc. Surg. - 1994. - № 108. - P. 1056-1065.; Thistlethwaite P.A., Kemp A., Du L., Madani M.M., Jamieson S.W. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension // J. Thorac. Cardiovasc. Surg. - 2012. - № 131. - P. 307-313.; Ogino H., Ando M., Matsuda H., Minatoya K. et al. Japanese single-center experience of surgery for chronic thromboembolic pulmonary hypertension // Ann. Thorac. Surg. - 2012. - № 82. - P. 630-636.; Saouti N., Morshuis W.J., Heijmen R.H., Snijder R.J. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience // Eur. J. Cardiothorac. Surg. - 2011. - № 35. - P. 947-952.; Jamieson S.W., Nomura K. Indications for and the results of pulmonary thromboendarterectomy for thromboembolic pulmonary hypertension // Semin. Vasc. Surg. - 2009. - № 13. - P. 236-244.; Corsico A.G., D’Armini A.M., Cerveri I., Klersy C. et al. Long-term outcome after pulmonary endarterectomy // Am. J. Respir. Crit. Care Med. - 2012. - № 178. - P. 419-424.; Mayer E. Surgical treatment of chronic thromboembolic pulmonary hypertension // Swiss Med. Weekly. - 2011. - № 136. - P. 491-497.; Saouti N., Morshuis W.J., Heijmen R.H., Snijder R.J. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience // Eur. J. Cardiothorac. Surg. - 2012. - № 35. - P. 947-952.; Чернявский А.М., Аляпкина Е.М., Мироненко С.П., Альсов С.А. и др. Динамика качества жизни у больных с хронической постэмболической легочной гипертензией после операции тромбэндартерэктомии из ветвей легочной артерии // Патология кровообращения и кардиохирургия. - 2010. - № 4. - P. 56-59.; Azarian R., Wartski M., Collignon M.A., Parent F. et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism // J. Nucl. Med. - 1997. - № 38. - P. 980-983.; Dixon J.E., King M.A. Images in clinical medicine. Chronic Thromboembolic Pulmonary Hypertension // N. Engl. J. Med. - 2012. - № 344. - P. 644-650.; Pattynama P.M. Meaning of a helical CT angiogram negative for pulmonary embolism // Radiology. - 2011. - № 218. - P. 913-916.; https://transmed.almazovcentre.ru/jour/article/view/27Test

الإتاحة: https://doi.org/10.18705/2311-4495-2014-0-2-72-7710.18705/2311-4495-2014-0-2Test
https://transmed.almazovcentre.ru/jour/article/view/27Test

مصطلحات موضوعية: 6 minute walking test, повторная ревматическая лихорадка, non-specific inflammation, тест 6-минутной ходьбы, реабилитация, хроническая ревматическая болезнь сердца, rehabilitation, physical training, quality of life, неспецифическое воспаление, физические тренировки, chronic rheumatic heart disease, repeated rheumatic fever, Cardiology and Cardiovascular Medicine, качество жизни

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::15557b1187bdc349eec877d2564fec09Test